4 Controversial Peptides, 4 Experimental Applications
As the FDA prepares to weigh in on the bulk manufacture of our favorite experimental peptides, we decided to gather our own questions about the compounds
Like what we write here? Support our work by liking and sharing — or by visiting the Peptide Partners website.
On Thursday, an FDA advisory committee will meet to discuss the bulk compounding fate of seven controversial peptides. The question at hand: is there enough evidence of these peptides’ clinical efficacy to recommend their bulk manufacture at specific compounding pharmacies? The committee will assess these peptides’ ability to treat certain disorders (e.g. ulcerative colitis, obesity, osteoporosis) and then make a non-binding recommendation to the FDA based on their deliberations.
Here at Peptide Partners, we believe in the immense research and clinical potential of peptides. And most importantly, we believe in the ability of scientific data to confirm and shape our understanding of that potential. Bring on the long-term studies and the randomized controlled trials! Who are we kidding? Bring back funding for the NSF and NIH!
Last week, we reported on some potential clinical applications for BPC-157, KPV, and TB-500 that we’d love to see investigated on the institutional level. This week, we’re diving exploring clinical applications and research questions for the other four peptides on the FDA advisory committee’s list: MOTs-C, Emideltide, Semax, and Epitalon.
Peptide Research, Done Cleanly — Peptide Partners. Independent HPLC/MS, batch COAs, and endotoxin screening to USP <85> validate identity and purity of peptides for research. Browse inventory and view certificates at Peptide Partners.
1. MOTs-C – AICAR production & AMPK activation
MOTs-C is a peptide encoded by mitochondrial DNA and rRNA. It’s been shown to mimic the effects of strenuous physical exercise by boosting insulin sensitivity on the cellular level, leading physicians to see it as a possible treatment for obesity and diabetes type II prevention. Some researchers believe the compound may have applications in the fields of longevity and biogerontology as well.
The only concern? Like other cell health and longevity-promoting peptides BPC-157 and TB-500, MOTs-C also promotes cellular growth. It will be up to research scientists to determine how the benefits of this powerful peptide can be harnessed without the potential threat of carcinogenesis in long-term use. Here at Peptide Partners Corner, we believe the answer may be partially related to how MOTs-C activates the proteins AICAR and AMPK.
AICAR (otherwise known as 5-amino-4-imidazolecarboxamide riboside) is a protein metabolite. AMPK (otherwise known as AMP-activated protein kinase) is “a highly conserved protein that acts as a sensor of energy metabolism and regulates various cellular functions such as autophagy and stress resistance.” AICAR “switches on” AMPK, which restores the balance of ATP – aka cellular energy – whenever it’s depleted. AMPK increases glucose uptake, glycolysis, fatty acid oxidation, and auto/mitophagy (the recycling of cellular material and damaged mitochondria). Questions to be answered: Can increased AMPK levels be harnessed to promote the phagocytosis of unhealthy cells? What effects does MOTs-C use produce in the short and long terms?
2. Emideltide – Circadian rhythm and addiction
Emideltide (aka Delta Sleep-Inducing Peptide) is a nonapeptide first isolated from the cerebral venous blood of rabbits who’d been induced to sleep. According to the US Department of Health and Human Services, emideltide has been shown to positively affect sleep patterns (the potential use it’s popularly associated with) as well as “electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal.”
The research data on emideltide aren’t just scarce – they’re virtually nonexistent. Since the three clinical applications the FDA advisory committee will be exploring for this peptide are “opioid withdrawal, chronic insomnia, and narcolepsy,” we at Peptide Partners Corner would love to see an RTC that measures emideltide’s effect on subjects’ circadian rhythms.
Unlike the data on emideltide, the scientific literature on the linkage between sleep disturbance and opioid dependency is quite robust. From a 1996 study measuring the effects of methadone and naltrexone treatment on the sleep patterns of addicts, to studies from 2020, 2022, and 2023 exploring the intersection of opioid dependency and sleep disturbance, researchers have been keen to unpack the relationship between sleep and addiction. Questions to answer: How does emideltide affect human circadian rhythms on the chemical level? How can regulated sleep cycles ameliorate chemical dependency?
3. Semax – brain-derived neurotrophic factor (BDNF) and memory
Semax is a peptide first synthesized by Russian scientists during the Cold War with the intention of treating ischemic stroke; it was later employed to enhance the cognition of individuals working in high-stress environments.
It’s a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH), specifically ACTH(4-10), modified with a Proline-Glycine-Proline (PGP) tail. That’s a highly technical way of saying that it’s a lab-produced neurotrophic peptide known to improve focus, memory, and mental clarity.
Semax achieves its positive cognitive effects through what’s called a “beneficial neurotrophic cascade,” which includes an increase in a protein called brain-derived neurotrophic factor. BDNF has been called “brain fertilizer” for the way it promotes the growth of new neurons and the “pruning” processes involved in memory and learning. We’d love to see research that isolates Semax’s effects on BDNF specifically, as well as studies that map its effect on memory-loss patients in the short and long-term. Questions to answer: What sort of relationship does Semax have to the production of BDNF? Can Semax’s neurotrophic effects benefit Alzheimer’s and dementia patients?
4. Epitalon – telomeres and aging
Epitalon is a tetrapeptide that was first synthesized from bovine pineal gland extract. It was first synthesized in the late 1980s by Vladimir Khavinson’s research team with the intention of determining whether the main effects of aging could be attributed to the declining function of the pineal gland.
Subsequent students have identified multiple epitalon-derived benefits in non-human subjects. A 2000 study found epitalon increased the lifespan of fruit flies by 11-16%. A 2005 study found that epitalon restored age-related disturbances in the function of rhesus monkeys’ pineal glands and pancreases. And then a 2025 study boasted this human-related headline: “Epitalon increases telomere length in human cell lines through telomerase up-regulation or ALT activity.”
A telomere is a region of repetitive DNA sequences that serves as the protective “cap” at the end of a chromosome. Telomeres prevent chromosomes from becoming frayed or entangled. Every time a cell divides, its telomeres shorten; the shorter the telomeres, the more likely it is to experience mitochondrial dysfunction and abnormal protein production. It becomes harder for tissues to repair themselves and for the body to maintain homeostasis, resulting in many of the effects of aging.
Questions to answer: Is epitalon-derived telomerase upregulation consistent across patients of different ages? What are the potential effects of long-term epitalon treatment?